Cart
sales@molnova.com
MK-3903
CAS No. 1219737-12-8
MK-3903 ( MK3903 )
Catalog No. M10828 CAS No. 1219737-12-8
MK-3903 is a potent and selective, direct and oral AMPK activator with EC50 of 9 nM.
Purity : >98% (HPLC)
COA
Datasheet
HNMR
HPLC
MSDS
Handing Instructions
| Size | Price / USD | Stock | Quantity |
| 2MG | 48 | In Stock |
|
| 5MG | 87 | In Stock |
|
| 10MG | 160 | In Stock |
|
| 25MG | 296 | In Stock |
|
| 50MG | 478 | In Stock |
|
| 100MG | 691 | In Stock |
|
| 500MG | 1422 | In Stock |
|
| 1G | Get Quote | In Stock |
|
Biological Information
-
Product NameMK-3903
-
NoteResearch use only, not for human use.
-
Brief DescriptionMK-3903 is a potent and selective, direct and oral AMPK activator with EC50 of 9 nM.
-
DescriptionMK-3903 is a potent and selective, direct and oral AMPK activator with EC50 of 9 nM; activates 10 of the 12 phosphorylated AMPK (pAMPK) complexes with EC50s of 8-40 nM, improves lipid metabolism and insulin sensitization in mice.
-
SynonymsMK3903
-
PathwayMembrane Transporter/Ion Channel
-
TargetAMPK
-
RecptorAMPK
-
Research Area——
-
Indication——
Chemical Information
-
CAS Number1219737-12-8
-
Formula Weight454.91
-
Molecular FormulaC27H19ClN2O3
-
Purity>98% (HPLC)
-
SolubilityDMSO: 70 mg/mL; Water: Insoluble; Ethanol: Insoluble （ < 1 mg/ml refers to the product slightly soluble or insoluble )
-
SMILESCC1=C(C=C(C=C1)OC2=NC3=C(N2)C=C(C(=C3)C4=CC=C(C=C4)C5=CC=CC=C5)Cl)C(=O)O
-
Chemical Name5-[(5-[1,1'-Biphenyl]-4-yl-6-chloro-1H-benzimidazol-2-yl)oxy]-2-methylbenzoic acid
Shipping & Storage Information
-
Storage(-20℃)
-
ShippingWith Ice Pack
-
Stability≥ 2 years
Reference
1. Lan P, et al. J Med Chem. 2017 Nov 9;60(21):9040-9052.
molnova catalog
related products
-
ASP4132
ASP4132 is an orally active AMPK activator (EC50 : 18 nM), has anti-cancer activity.
-
Adenosine 5-monophos...
Adenine nucleotide containing one phosphate group esterified to the sugar moiety in the 2'-, 3'-, or 5'-position.
-
Onjisaponin B
Onjisaponin B induces autophagy via the AMPK-mTOR signaling pathway, increases the NGF level and accelerates both the removal of mutant huntingtin and A53T α±-synuclein, it may have potential therapeutic effects on Parkinson disease, Alzheimer disease and Huntington disease.
